Just a sample from another industry....

Since edig has already delivered the goods, unlike in the drug industry (below) we cannot offer up the total value of the Sri Lankan deal without essentially tipping our hand. Revenues will come out in 10Q right.....

The second licensing deal that Johnson & Johnson struck yesterday was definitely for diabetes drugs, but given the terse press release, it's hard to say much more. The deal was for "several" preclinical compounds developed by Metabolex. The drugs treat "type 2 diabetes and other disorders." Johnson & Johnson is on the hook for "development, regulatory, and commercial milestones up to $330 million," but the companies didn't break out how much was allocated to each. Oh, and there's an (unknown) up-front payment, too.

The vagueness of the press release is understandable, given the early stage of the development -- no need to tip off potential competitors -- but it does make it hard to know if Johnson & Johnson got a good deal.